Compound 19A8.8

• Description :

  Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis[1].

• UNSPSC :

  12352209

• Target :

  TGF-beta/Smad; TGF-β Receptor

• Related Pathways :

  Stem Cell/Wnt; TGF-beta/Smad

• Field of Research :

  Neurological Disease

• Smiles :

  O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(N[C@H]1CC(O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)NC1=O

• Molecular Formula :

  C35H60N12O13

• Molecular Weight :

  856.92

• References & Citations :

  [1]Zhang W, et al. Design and discovery of novel cyclic peptides as TSP1-CD36 interaction inhibitors for intestinal fibrosis treatment. Bioorg Chem. 2025 Aug;163:108667.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported